A Phase I, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ulimorelin (LP101)
Latest Information Update: 23 Feb 2021
At a glance
- Drugs Ulimorelin (Primary)
- Indications Nutrition disorders
- Focus Pharmacokinetics
- Sponsors Lyric Pharmaceuticals
- 05 Jun 2018 Results presented at the Digestive Disease Week 2018
- 16 Dec 2016 New trial record